Stock Ratings / Health Care / ANIP / dividends

NUVB (29) CMPS (37) STOK (59) RARE (26) ⌘ Pro Terminal →

ANI Pharmaceuticals Inc. (ANIP) Dividend Safety Gauge & 10-Year DRIP Compounder

$73.16 +2.02% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

ANI Pharmaceuticals Inc. (ANIP) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (steady margins, 16% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B- • BUY Cap $1.68B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B-

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk C+

Each axis scored 0–20

12M PRICE TARGET CONE+5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ANIP)Realized 20D OHLCV Swing Band: ±5.7%

CASH DIVIDEND + BUYBACK YIELD

1.87% Total Yield

0.07% Cash ($0.05/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

88/100 • FORTRESS PAYOUT

FREE CASH FLOW PAYOUT RATIO

14% of FCF

8 consecutive years of payout growth

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (16.4% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $45,659

Est. Year-10 Shareholder Yield: $854/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$11.6K

Yr 1

$13.5K

Yr 2

$15.8K

Yr 3

$18.4K

Yr 4

$21.4K

Yr 5

$24.9K

Yr 6

$29.0K

Yr 7

$33.7K

Yr 8

$39.2K

Yr 9

$45.7K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in ANIP & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on ANIP and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ANIP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -7.92%▼ DESCENDING CHANNEL

2026-10-30O $73.27H $73.54L $71.90C $73.16VOL 286.9K

RES: $75.18SUP: $64.27SMA50: $72.95SMA200: $77.65

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANIP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ANIP Butterfly Map → + Track ANIP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

15.2%/yr Implied 5Y Growth

vs. +43.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ANIP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ANIP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ANIP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANIP)

Health Care Rank #92 of 1016 ⚔️ NUVB vs ANIP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ANIP vs. NUVB, CMPS, STOK, RARE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ANI Pharmaceuticals Inc. (ANIP) ranks #92 by composite RQD confidence (70/100, grade B-) and #289 by equity capitalization ($1.68B). Within this direct 5-issuer industry benchmark cohort, ANIP leads on earnings valuation at 21.5x trailing P/E, while ANIP leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. ANIP currently leads its immediate peer cohort in composite quantitative strength at 70/100 (B-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ANIP ACTIVE ANI Pharmaceuticals Inc.	B-	70/100	21.5x	—	16.0%	+2.02%	$1.68B	Benchmark Subject
NUVB Nuvation Bio Inc. (Class A)	E	29/100	—	—	-35.0%	+3.92%	$1.67B	/nuvb-vs-anip →
CMPS COMPASS Pathways Plc American Depository Shares	D-	37/100	—	—	-35.0%	-0.73%	$1.69B	/cmps-vs-anip →
STOK Stoke Therapeutics Inc.	C-	59/100	—	—	-6.1%	-0.23%	$1.70B	/stok-vs-anip →
RARE Ultragenyx Pharmaceutical Inc.	E	26/100	—	—	-35.0%	-2.44%	$1.65B	/rare-vs-anip →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001023024

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ANI Pharmaceuticals Inc. (ANIP) reported GAAP revenue of $883.4M (+43.8% vs. FY2024 revenue of $614.4M , and +81.5% cumulative change since FY2023) , GAAP net income of $78.0M, operating cash flow of $185.2M, and free cash flow of $171.4M (+258.7% YoY). On the balance sheet, ANIP closed FY2025 with $1.44B in total assets against $291.8M in total debt (Altman Z-Score: 2.36, Piotroski F-Score: 8/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$883.4M	$78.0M	$185.2M	$171.4M	$1.44B	$291.8M
FY2024 (FY)	2024-12-31	$614.4M	-$19.0M	$64.0M	$47.8M	$1.28B	$309.1M
FY2023 (FY)	2023-12-31	$486.8M	$19.0M	$119.0M	$119.0M	—	—

3. ANIP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANIP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ANI Pharmaceuticals Inc. (NASDAQ: ANIP) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $73.16 (+2.02% 1D, market cap $1.68B). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, ANIP ranks #92 in composite RQD confidence.

How does ANIP compare to NUVB and CMPS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ANIP carries a Roarable B- (70/100 RQD), trailing P/E of 21.5x, gross margin of —, and ROIC of 16.0%. By comparison, NUVB (Nuvation Bio Inc. (Class A)) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $1.67B) and CMPS (COMPASS Pathways Plc American Depository Shares) posts a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $1.69B). Among the 5-stock peer group, ANIP leads on earnings multiple (21.5x) while ANIP leads on capital efficiency (16.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANIP?

Per ANIP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001023024), ANI Pharmaceuticals Inc. generated $883.4M in revenue (+43.8% YoY), $78.0M in net income, and $171.4M in free cash flow against $1.44B in total assets and $291.8M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANIP trading relative to its 50-day, 200-day, and 52-week technical levels?

ANIP last traded at $73.16 (+2.02% on volume of 262,430 shares), positioning the stock +0.29% above its 50-day simple moving average ($72.95) and -5.78% below its 200-day simple moving average ($77.65). Across its 52-week range of $69.58 to $95.57, ANIP sits at the 13.8% percentile with a 14-day RSI of 47.2 (NEUTRAL RANGE) and an implied next-earnings move of ±5.7% ($68.99 to $77.33).

ANIP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does ANIP pay a dividend and is it safe?

ANI Pharmaceuticals Inc. (ANIP) offers a 0.07% cash dividend yield ($0.05 annualized) and 1.87% total shareholder yield including buybacks. Roarable rates its payout coverage as FORTRESS PAYOUT.

Direct Sub-Reports: ANIP RQD Cockpit ANIP 12M Forecast ANIP Earnings & Move ANIP Dividends & DRIP ANIP Insiders & 13F ANIP Whale Options ANIP Profit Sankey ANIP News & Why